September 27, 2016 11:40 AM ET

Pharmaceuticals

Company Overview of Shire Human Genetic Therapies, Inc.

Key Executives for Shire Human Genetic Therapies, Inc.

NameBoard RelationshipsTitleAge
Søren Tulstrup M.ScNo RelationshipsSenior Vice President and Franchise Lead of Mucopolysaccharides51
Marcio Voloch Ph.D.No RelationshipsVice President of Process Development--
Daniella M. Lutz No RelationshipsCorporate Communications Manager--

Shire Human Genetic Therapies, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Jonathan S. Leff M.B.A 177 RelationshipsDeerfield Management Company, L.P.47
Rodman W. Moorhead III 92 RelationshipsScientific Learning Corp.72
View All Board Members

Shire Human Genetic Therapies, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Nominating Committee M.B.AJonathan S. Leff177 Relationships1 Executives
Corporate Governance Committee M.B.AJonathan S. Leff177 Relationships1 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary
405.9K
Bonus
514.1K
Total Short Term Compensation
594.9K
Total Value of Options
14.4M
Compensation as of Fiscal Year
Shire Human Genetic Therapies, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Imprimis Pharmaceuticals, Inc. Announces the Resignation of William H. Nelson as Independent Director and from All Board Committee Positions, Effective Immediately
September 26, 2016 9:00 PM ET
Jounce Therapeutics, Inc. Appoints Stephen Farrand as Chief Technical Officer
September 26, 2016 1:11 PM ET
Nouscom Announces Management Appointments
September 26, 2016 6:00 AM ET
Tyche Industries Ltd Announces the Resignation of G Sandeep as Whole Time Director and Chief Financial Officer
September 24, 2016 12:00 AM ET
Endo International plc Announces Executive Changes
September 23, 2016 11:00 AM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Shire Human Genetic Therapies, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.